It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment prolongs survival.

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the presentation of four posters at the American Urological ...

A newly published study involving researchers from Karolinska Institutet indicates that prostate cancer can be diagnosed at ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Prostate cancer is the most common cancer in men worldwide. Thanks to scientific breakthroughs, there are more ways than ever to treat it — especially when it’s caught early. One ...

Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) of the ENLIGHTED Phase 3 ...

Loyola High volleyball coach Michael Boehle learns how to deal with prostate cancer that fortunately was diagnosed early and ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from its market-leading Decipher Prostate ...

"After a while, I forgot that I was doing a remote surgery," Cleveland Clinic urologist Dr. Ruben Olivares said of EDAP's ...

In a Maple Grove industrial strip mall unequipped with the beanbag chairs common to Silicon Valley startups, Francis Medical ...

The Tata Memorial Centre has launched the 'MenCan' initiative to address rising prostate, penile, and testicular cancers ...